Andreas Engert
Impact in
- Pathology and Forensic Medicine top 0.01%
- Lymphoma Diagnosis and Treatment
- Hematology top 0.5%
- Erythropoietin and Anemia Treatment
Papers in
-
- Lymphoma Diagnosis and Treatment 392
- Hematology 41
- Erythropoietin and Anemia Treatment 16
- Hematopoietic Stem Cell Transplantation 14
- Co-authors
- Volker Diehl (191 shared papers)Peter Borchmann (180 shared papers)Dennis Alexander Eichenauer (73 shared papers)Andreas Josting (58 shared papers)Bastian von Tresckow (94 shared papers)Michael Fuchs (103 shared papers)Julia Bohlius (30 shared papers)Anas Younes (18 shared papers)
- Journals
- Blood (129 papers)Journal of Clinical Oncology (52 papers)Annals of Oncology (49 papers)Cochrane Database of Systematic Reviews (32 papers)British Journal of Haematology (18 papers)
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
Andreas Engert
571 papers receiving 27.5k citations
Andreas Engert's Hit Papers
Peers
Comparison fields: 5 of 147
- Pathology and Forensic Medicine 15k
- Hematology 2.3k
- Oncology 3.1k
- Genetics 1.1k
- Immunology 2.1k
Countries citing papers authored by Andreas Engert
This map shows the geographic impact of Andreas Engert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Engert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Engert more than expected).
Fields of papers citing papers by Andreas Engert
This network shows the impact of papers produced by Andreas Engert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Engert. The network helps show where Andreas Engert may publish in the future.
Co-authors
The 25 scholars most cited alongside Andreas Engert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 596 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma Hit paper breakdown → | 2012 | 1214 |
| 2 | Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial Hit paper breakdown → | 2016 | 776 |
| 3 | Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma Hit paper breakdown → | 2010 | 701 |
| 4 | Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial Hit paper breakdown → | 2018 | 569 |
| 5 | Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8) Hit paper breakdown → | 1999 | 568 |
| 6 | Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial Hit paper breakdown → | 2012 | 465 |
| 7 | Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials Hit paper breakdown → | 2009 | 460 |
| 8 | 2006 | 433 | |
| 9 | 2009 | 374 | |
| 10 | Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2014 | 369 |
| 11 | 2003 | 342 | |
| 12 | 2003 | 340 | |
| 13 | 2010 | 327 | |
| 14 | Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma Hit paper breakdown → | 2016 | 321 |
| 15 | 2007 | 296 | |
| 16 | Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2018 | 291 |
| 17 | A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma Hit paper breakdown → | 2015 | 285 |
| 18 | PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group Hit paper breakdown → | 2017 | 273 |
| 19 | 2017 | 261 | |
| 20 | 2003 | 251 |
About Andreas Engert
Andreas Engert is a scholar working on Pathology and Forensic Medicine, Hematology, Immunology, Oncology and Genetics, having authored 596 papers that have together received 28.5k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (392 papers), Toxin Mechanisms and Immunotoxins (29 papers), Neutropenia and Cancer Infections (22 papers), Chronic Lymphocytic Leukemia Research (22 papers), Erythropoietin and Anemia Treatment (16 papers), Advanced Radiotherapy Techniques (14 papers), Hematopoietic Stem Cell Transplantation (14 papers) and CNS Lymphoma Diagnosis and Treatment (13 papers). The work is most often cited by research in Pathology and Forensic Medicine (15k citations), Hematology (2.3k citations), Oncology (3.1k citations), Genetics (1.1k citations) and Immunology (2.1k citations). Andreas Engert has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Volker Diehl, Peter Borchmann, Dennis Alexander Eichenauer, Andreas Josting, Bastian von Tresckow, Michael Fuchs, Julia Bohlius, Anas Younes, Thomas Elter and Stephen Maxted Ansell. Their work appears in journals such as Blood, Journal of Clinical Oncology, Annals of Oncology, Cochrane Database of Systematic Reviews and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.